66 related articles for article (PubMed ID: 20656362)
1. Is newer always better? Re-evaluating the benefits of newer pharmaceuticals.
Law MR; Grépin KA
J Health Econ; 2010 Sep; 29(5):743-50. PubMed ID: 20656362
[TBL] [Abstract][Full Text] [Related]
2. The effect of newer drugs on health spending: do they really increase the costs?
Civan A; Köksal B
Health Econ; 2010 May; 19(5):581-95. PubMed ID: 19404925
[TBL] [Abstract][Full Text] [Related]
3. Gender disparities in medical expenditures attributable to hypertension in the United States.
Basu R; Franzini L; Krueger PM; Lairson DR
Womens Health Issues; 2010; 20(2):114-25. PubMed ID: 20211429
[TBL] [Abstract][Full Text] [Related]
4. The concentration and persistence of health care expenditures and prescription drug expenditures in Medicare beneficiaries with Alzheimer disease and related dementias.
Lin PJ; Biddle AK; Ganguly R; Kaufer DI; Maciejewski ML
Med Care; 2009 Nov; 47(11):1174-9. PubMed ID: 19786913
[TBL] [Abstract][Full Text] [Related]
5. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
6. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
7. Health expenditure estimation and functional form: applications of the generalized gamma and extended estimating equations models.
Hill SC; Miller GE
Health Econ; 2010 May; 19(5):608-27. PubMed ID: 19434646
[TBL] [Abstract][Full Text] [Related]
8. Differences in medical expenditure according to drug prices.
Ueshima H
Hypertens Res; 2006 May; 29(5):301-2. PubMed ID: 16832148
[No Abstract] [Full Text] [Related]
9. The cost effect of newer medication adoption in an older Medicaid cohort.
Shireman TI; Rigler SK; Jachna CM; Griebling TL; Eng ML
J Am Geriatr Soc; 2005 Aug; 53(8):1366-73. PubMed ID: 16078963
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive drug prescription trends at the primary health care centres in Bahrain.
Jassim al Khaja KA; Sequeira RP; Wahab AW; Mathur VS
Pharmacoepidemiol Drug Saf; 2001 May; 10(3):219-27. PubMed ID: 11501335
[TBL] [Abstract][Full Text] [Related]
11. Economic costs and benefits of treating mild hypertension: results from a cross-sectional model.
Millar JA; Hansen PC
N Z Med J; 1988 Oct; 101(855):623-5. PubMed ID: 3140147
[TBL] [Abstract][Full Text] [Related]
12. Cost-offsets of prescription drug expenditures: data analysis via a copula-based bivariate dynamic hurdle model.
Deb P; Trivedi PK; Zimmer DM
Health Econ; 2014 Oct; 23(10):1242-59. PubMed ID: 23956147
[TBL] [Abstract][Full Text] [Related]
13. Are there unintended consequences of step-therapy programs?
Cox ER; Seiz BJ
Am J Manag Care; 2009 Sep; 15(9):654, 656; author reply 656. PubMed ID: 19747030
[No Abstract] [Full Text] [Related]
14. Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada.
Hanley GE; Morgan S
Soc Sci Med; 2009 Mar; 68(5):919-24. PubMed ID: 19135288
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the total cost of treating elderly hypertensive patients with ACE inhibitors: a comparison of older and newer agents.
Small RE; Freeman-Arnold SB; Goode JV; Pyles MA
Pharmacotherapy; 1997; 17(5):1011-6. PubMed ID: 9324190
[TBL] [Abstract][Full Text] [Related]
16. Estimated annual direct expenditures in the United States as a result of inappropriate hypertension treatment according to national treatment guidelines.
Balu S
Clin Ther; 2009 Jul; 31(7):1581-94. PubMed ID: 19695408
[TBL] [Abstract][Full Text] [Related]
17. Changing prescription patterns: impact on costs.
Bock KD
J Hypertens Suppl; 1987 Aug; 5(3):S83-5. PubMed ID: 3478431
[TBL] [Abstract][Full Text] [Related]
18. Economics of suboptimal drug use: cost-savings of using JNC-recommended medications for management of uncomplicated essential hypertension.
Xu KT; Moloney M; Phillips S
Am J Manag Care; 2003 Aug; 9(8):529-36. PubMed ID: 12921230
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic challenges in disease management of hypertension.
Ambrosioni E
J Hypertens Suppl; 2001 Sep; 19(3):S33-40. PubMed ID: 11713849
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
Wilson TW; Chockalingam A; Quest DW
J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
